Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents

Definitions

• This invention relates to a nutritional supplement for pregnant women to reduce the risk of obesity of the baby in later life.
• DHA in particular is accumulated preferentially to other fatty acids by the foetus in the last trimester of pregnancy. In premature birth, this period does not last the full three months and it may be expected that the response of the pre-term infant to supplementation with DHA would be marked.
• a term infant would have the benefit of maternal supply during the last three months of gestation and, assuming that supply to be adequate, could be expected to have adequate or near adequate DHA status at birth.
• WO 2004/012727 discloses a method for decreasing the appetite of a mammal comprising enterally administering an omega 3 LC-PUFA to the mammal.
• Ruzickova J. et al. Lipids. 2004 Dec;39(12): 1177-85
• Lauritzen L. et al. (Maternal fish oil supplementation in lactation and growth during the first 2.5 years of life. Pediatr Res. 2005 Aug;58(2):235-42) performed a randomized trial on mothers after delivery. The women were randomly assigned to take a supplement of fish oil (rich in omega 3 LC-PUFA such as DHA) or olive oil. The supplement was taken during 0 to 4 months of lactation. 122 children were studied of whom 70 were followed up until 30 months. The BMI of the children was measured at birth and at 2, 4, 9 and 30 months of age. The results showed that the BMI of infants in the fish oil group was higher than the BMI of infants in the olive oil group from the age of 9 months on.
• the inventors have conducted a study investigating the effect of a daily oral supplement containing DHA on red blood cell phospholipid DHA concentration in pregnant women at 37 weeks of gestation and whether a daily oral intake of DHA influences the DHA concentrations in breast-milk or/and red blood cell phospholipids in mother and/or infant during lactation. During this study, it was surprisingly found that the weight and body mass index of children in the DHA supplemented group at age 21 months were significantly lower than the weight and body mass index of children in the group not receiving DHA.
• the present invention provides the use of docosahexaenoic acid in the manufacture of a composition for administration to a pregnant woman in at least the third trimester of pregnancy and, after delivery, to the newborn baby for a period not exceeding three months for reducing the risk of development of overweight or obesity of the baby in infancy and/or early childhood.
• the present invention provides the use of docosahexaenoic acid in the manufacture of a composition for administration to a pregnant woman for reducing the risk of development of overweight or obesity of the baby in infancy and/or early childhood.
• the present invention provides the use of docosahexaenoic acid in the manufacture of a composition for administration to a pregnant women to promote the development of lean body mass of the baby in infancy and/or early childhood.
• the invention extends to a method of reducing the risk of obesity of a baby in infancy and/or early childhood by providing to a pregnant woman in need thereof a composition containing a therapeutic amount of docosahexaenoic acid.
• the invention further extends to a method of promoting the development of lean body mass of a baby in infancy and/or early childhood by providing to a pregnant woman in need thereof a composition containing a therapeutic amount of docosahexaenoic acid.
• the composition may either be administered to the infant via the breast feeding mother or may be administered directly to the infant.
• the daily dose of DHA for a pregnant woman is preferably between 100 and 500 mg, more preferably between 200 and 400 mg.
• the amount of DHA in the composition may thus be selected accordingly depending upon whether it is intended to be consumed once a day or more frequently.
• a composition intended to be consumed once a day may contain 200 mg of DHA.
• Suitable sources of DHA include fish oil and biomass obtained from the culture of a suitable micro-organism such as Crypthecodium cohnii .
• the composition is preferably taken throughout pregnancy to build up maternal stores of DHA although supplementation in the second and more particularly the third trimesters is believed to be particularly advantageous.
• supplementation may continue after birth either via continued consumption of the composition by the mother if the baby is to be breast fed or by administering DHA to the baby, for example by including DHA in the infant formula used to feed the baby.
• a suitable DHA content in infant formula ranges between 0.2 and 0.8% by weight of total fatty acids in the formula.
• the composition is a nutritional composition.
• the composition may be a nutritionally complete formula, a nutritional supplement, a food product such as a dairy product, a chilled or shelf stable beverage or a soup, a dietary supplement, a meal replacement, or a nutritional bar for example.
• a nutritionally complete formula for use according to the invention may comprise a source of protein.
• Any suitable dietary protein may be used for example animal proteins (such as milk proteins, meat proteins and egg proteins); vegetable proteins (such as soy protein, wheat protein, rice protein, and pea protein); mixtures of free amino acids; or combinations thereof. Milk proteins such as casein and whey, and soy proteins are particularly preferred.
• the composition may also contain a source of carbohydrates and a source of fat.
• the fat source preferably provides 5% to 40% of the energy of the formula; for example 20% to 30% of the energy.
• a suitable fat profile may be obtained using a blend of canola oil, corn oil and high-oleic acid sunflower oil.
• a source of carbohydrate may be added to the formula. It preferably provides 40% to 80% of the energy of the formula. Any suitable carbohydrate may be used, for example sucrose, lactose, glucose, fructose, corn syrup solids, maltodextrins, and mixtures thereof. Dietary fibre may also be added if desired. Dietary fibre passes through the small intestine undigested by enzymes and functions as a natural bulking agent and laxative. Dietary fibre may be soluble or insoluble and in general a blend of the two types is preferred.
• Suitable sources of dietary fibre include soy, pea, oat, pectin, guar gum, gum Arabic, fructooligosaccharides, galacto-oligosaccharides, sialyl-lactose and oligosaccharides derived from animal milks.
• a preferred fibre blend is a mixture of inulin with shorter chain fructo-oligosaccharides.
• the fibre content is between 10 and 40 g/l of the formula as consumed.
• the formula may also contain minerals and micronutrients such as trace elements and vitamins in accordance with the recommendations of Government bodies such as the USRDA.
• the formula may contain per daily dose one or more of the following micronutrients in the ranges given:- 300 to 500 mg calcium, 50 to 100 mg magnesium, 150 to 250 mg phosphorus, 5 to 20 mg iron, 1 to 7 mg zinc, 0.1 to 0.3 mg copper, 50 to 200 ⁇ g iodine, 5 to 15 ⁇ g selenium, 1000 to 3000 ⁇ g beta carotene, 10 to 80 mg Vitamin C, 1 to 2 mg Vitamin B1, 0.5 to 1.5 mg Vitamin B6, 0.5 to 2 mg Vitamin B2, 5 to 18 mg niacin, 0.5 to 2.0 ⁇ g Vitamin B12, 100 to 800 ⁇ g folic acid, 30 to 70 ⁇ g biotin, 1 to 5 ⁇ g Vitamin D, 3 to 10 IU Vitamin E.
• a probiotic bacterial strain may be added to the formula.
• One example of a suitable strain is Lactobacillus rhamnosus CGMCC 1.3724.
• One or more food grade emulsifiers may be incorporated into the formula if desired; for example diacetyl tartaric acid esters of mono- and di- glycerides, lecithin and mono- and di-glycerides. Similarly suitable salts and stabilisers may be included.
• the formula is preferably enterally administrable; for example in the form of a powder or a liquid concentrate for re-constitution with milk or water, a solid product or a ready-to-drink beverage.
• the formula may be prepared in any suitable manner. For example, it may be prepared by blending together the protein, the carbohydrate source, and the fat source including the DHA in appropriate proportions. If used, the emulsifiers may be included at this point. The vitamins and minerals may be added at this point but are usually added later to avoid thermal degradation. Any lipophilic vitamins, emulsifiers and the like may be dissolved into the fat source prior to blending. Water, preferably water which has been subjected to reverse osmosis, may then be mixed in to form a liquid mixture. The temperature of the water is conveniently about 50° C. to about 80° C. to aid dispersal of the ingredients. Commercially available liquefiers may be used to form the liquid mixture. The liquid mixture is then homogenised; for example in two stages.
• the liquid mixture may then be thermally treated to reduce bacterial loads, by rapidly heating the liquid mixture to a temperature in the range of about 80° C. to about 150° C. for about 5 seconds to about 5 minutes, for example.
• This may be carried out by steam injection, autoclave or by heat exchanger; for example a plate heat exchanger.
• the liquid mixture may be cooled to about 60° C. to about 85° C.; for example by flash cooling.
• the liquid mixture may then be again homogenised; for example in two stages at about 10 MPa to about 30 MPa in the first stage and about 2 MPa to about 10 MPa in the second stage.
• the homogenised mixture may then be further cooled to add any heat sensitive components; such as vitamins and minerals.
• the pH and solids content of the homogenised mixture are conveniently adjusted at this point.
• the homogenised mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
• a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
• the powder should have a moisture content of less than about 5% by weight.
• the homogenised mixture is preferably aseptically filled into suitable containers by pre-heating the homogenised mixture (for example to about 75 to 85° C.) and then injecting steam into the homogenised mixture to raise the temperature to about 140 to 160° C.; for example at about 150° C.
• the homogenised mixture may then be cooled, for example by flash cooling, to a temperature of about 75 to 85° C.
• the homogenised mixture may then be homogenised, further cooled to about room temperature and filled into containers. Suitable apparatus for carrying out aseptic filling of this nature is commercially available.
• the liquid composition may be in the form of a ready to feed formula having a solids content of about 10 to about 14% by weight or may be in the form of a concentrate; usually of solids content of about 20 to about 26% by weight.
• a conventional food product such as a yoghurt, or a breakfast cereal may be enriched with the DHA.
• a supplement containing DHA in an amount sufficient to achieve the desired effect in an individual can be prepared.
• This supplement may be in the form of tablets, capsules, pastilles or a liquid for example.
• the supplement may further contain protective hydrocolloids (such as gums, proteins, modified starches), binders, film forming agents, encapsulating agents/materials, wall/shell materials, matrix compounds, coatings, emulsifiers, surface active agents, solubilizing agents (oils, fats, waxes, lecithins etc.), adsorbents, carriers, fillers, co-compounds, dispersing agents, wetting agents, processing aids (solvents), flowing agents, taste masking agents, weighting agents, jellifying agents, gel forming agents, antioxidants and antimicrobials.
• protective hydrocolloids such as gums, proteins, modified starches
• binders film forming agents
• encapsulating agents/materials, wall/shell materials such as binders, film forming agents, en
• the supplement may also contain conventional pharmaceutical additives and adjuvants, excipients and diluents, including, but not limited to, water, gelatine of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavouring agents, preservatives, stabilizers, emulsifying agents, buffers, lubricants, colorants, wetting agents, fillers, and the like.
• conventional pharmaceutical additives and adjuvants, excipients and diluents including, but not limited to, water, gelatine of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavouring agents, preservatives, stabilizers, emulsifying agents, buffers, lubricants, colorants, wetting agents, fillers, and the like.
• the supplement may contain an organic or inorganic carrier material suitable for oral or enteral administration as well as vitamins, minerals trace elements and other micronutrients in accordance with the recommendations of Government bodies such as the USRDA.
• the supplement may contain one or more of the following micronutrients in the ranges given:- 300 to 500 mg calcium, 50 to 100 mg magnesium, 150 to 250 mg phosphorus, 5 to 20 mg iron, 1 to 7 mg zinc, 0.1 to 0.3 mg copper, 50 to 200 jig iodine, 5 to 15 ⁇ g selenium, 1000 to 3000 ⁇ g beta carotene, 10 to 80 mg Vitamin C, 1 to 2 mg Vitamin B1, 0.5 to 1.5 mg Vitamin B6, 0.5 to 2 mg Vitamin B2, 5 to 18 mg niacin, 0.5 to 2.0 ⁇ g Vitamin B12, 100 to 800 ⁇ g folic acid, 30 to 70 ⁇ g biotin, 1 to 5 ⁇ g Vitamin D, 3 to 10 IU Vitamin E.
• This example compares the effect of administering a nutritional supplement including DHA to pregnant women with the effect of administration of the same supplement but without the DHA to a comparable group of pregnant women on the evolution of weight and body mass of their children.
• All supplements were in the form of a shelf-stable liquid containing per serving 4.6 g protein and 25 g carbohydrate, vitamins and minerals.
• the supplement for Groups 2 and 3 contained 3.8 g per serving of a mixture of short and long chain fructo-oligosaccharides produced by the hydrolysis of inulin and the supplement for Group 3 contained 0.26 g per serving DHA.
• 190 ml of the supplement was taken per day in all groups delivering 120 kcal for Groups 1 and 2 and 130 kcal for Group 3. The supplement was taken for the remainder of the pregnancy and for the first three months of lactation.
• the DHA concentration as a % of total fatty acids at 3 months in breastmilk in Group 1 subjects was 0.25 (+/ ⁇ 0.10) compared to 0.26 (+/ ⁇ 0.13), and 0.50 (+/ ⁇ 0.19) in Group 2 and Group 3 subjects, respectively.
• the treatment effect was significant in Group 3 compared to Groups 1 and 2.
• the red blood cell DHA concentration (% of total fatty acids) at 3 months in babies in Group 1 was 7.49 (+/ ⁇ 2.00) compared to 6.88 (+/ ⁇ 2.76) in Group 2, and 9.79 (+/ ⁇ 2.21) in Group 3. Again, the treatment effects were significantly different.
• the omega 6:omega 3 ratio in the red blood cells of the women in Groups 1 and 2 was 2:1 compared to 1.55:1 for the women in Group 3.
• the omega 6:omega 3 ratio in breastmilk of the women in Groups 1 and 2 was also 2:1 compared to 0.85:1 for the women in Group 3 and the omega 6:omega 3 ratio in the red blood cells of the babies in Groups 1 and 2 at 3 months of age was 2.4:1 compared to 1.6:1 for the babies of women in Group 3 at the same age.

Landscapes

• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Obesity (AREA)
• Child & Adolescent Psychology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Nutrition Science (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=36758415

Family Applications (2)

Family Applications After (1)

Country Status (14)

Cited By (3)

Families Citing this family (24)

Citations (6)

Family Cites Families (13)

• 2006
  • 2006-05-23 EP EP06114360A patent/EP1886680A1/fr not_active Withdrawn
• 2007
  • 2007-05-22 ES ES07729358T patent/ES2423682T5/es active Active
  • 2007-05-22 MY MYPI20084665A patent/MY149914A/en unknown
  • 2007-05-22 WO PCT/EP2007/054916 patent/WO2007135141A1/fr active Application Filing
  • 2007-05-22 CN CNA2007800233315A patent/CN101472578A/zh active Pending
  • 2007-05-22 BR BRPI0711797-3A patent/BRPI0711797A2/pt not_active IP Right Cessation
  • 2007-05-22 CA CA002653091A patent/CA2653091A1/fr not_active Abandoned
  • 2007-05-22 AU AU2007253309A patent/AU2007253309B2/en active Active
  • 2007-05-22 MX MX2008014808A patent/MX2008014808A/es active IP Right Grant
  • 2007-05-22 PT PT77293587T patent/PT2026791E/pt unknown
  • 2007-05-22 PL PL07729358T patent/PL2026791T3/pl unknown
  • 2007-05-22 EP EP07729358.7A patent/EP2026791B2/fr active Active
  • 2007-05-22 US US12/301,723 patent/US20090142314A1/en not_active Abandoned
  • 2007-05-22 RU RU2008150859/15A patent/RU2457836C2/ru active
• 2008
  • 2008-12-22 ZA ZA200810799A patent/ZA200810799B/xx unknown
• 2011
  • 2011-10-07 US US13/269,284 patent/US8454950B2/en active Active

Patent Citations (6)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events